<DOC>
	<DOC>NCT00699790</DOC>
	<brief_summary>The purpose of the study is to determine whether a CCR2 antagonist (BMS-741672) improves glucose homeostasis in drug-naive type 2 diabetic patients</brief_summary>
	<brief_title>Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance</brief_title>
	<detailed_description />
	<criteria>Drugnaive Type 2 diabetics with a screening HbA1c of ≥ 7.5% and ≤ 10% Screening FPG ≥ 140 mg/dL and ≤ 220 mg/dL BMI ≤ 40 kg/m2 Active tuberculosis Symptoms of poorly controlled diabetes History of diabetic ketoacidosis Significant cardiovascular history or gastrointestinal disorders History of unstable or rapidly progressing renal disease Active liver disease and/or significant abnormal liver function Abnormal chest xray at screening indicative of tuberculosis or other infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>NOS</keyword>
</DOC>